Chitnis, Tanuja http://orcid.org/0000-0002-9897-4422
Qureshi, Ferhan http://orcid.org/0000-0002-5158-0485
Gehman, Victor M.
Becich, Michael http://orcid.org/0000-0003-4687-8751
Bove, Riley http://orcid.org/0000-0002-2034-8800
Cree, Bruce A. C.
Gomez, Refujia
Hauser, Stephen L. http://orcid.org/0000-0002-4932-4001
Henry, Roland G. http://orcid.org/0000-0002-8232-7562
Katrib, Amal
Lokhande, Hrishikesh
Paul, Anu
Caillier, Stacy J.
Santaniello, Adam http://orcid.org/0000-0002-9816-5932
Sattarnezhad, Neda
Saxena, Shrishti
Weiner, Howard http://orcid.org/0000-0003-0203-9681
Yano, Hajime
Baranzini, Sergio E. http://orcid.org/0000-0003-0067-194X
Funding for this research was provided by:
U.S. Department of Defense (W81XWH2110633)
Article History
Received: 16 June 2023
Accepted: 7 May 2024
First Online: 20 May 2024
Competing interests
: The authors declare the following competing interests: T.C. has received compensation for consulting from Biogen, Novartis Pharmaceuticals, Roche Genentech, and Sanofi Genzyme, and received research support from the National Institutes of Health, National MS Society, US Department of Defense, EMD Serono, I-Mab Biopharma, Novartis Pharmaceuticals, Octave Bioscience, Inc, Roche Genentech, and Tiziana Life Sciences. V.M.G., M.B., and A.K. were employees of Octave Bioscience, Inc at the time the study was completed. R.B. is funded by the NMSS Harry Weaver Award, NIH, DOD, NSF, as well as Biogen, Novartis, and Roche Genentech. She has received personal fees for consulting from Alexion, EMD Serono, Horizon, Janssen, Sanofi-Genzyme, and TG Therapeutics. B.A.C.C. has received personal compensation for consulting from Alexion, Atara, Autobahn, Avotres, Biogen, Boston Pharma, EMD Serono, Gossamer Bio, Hexal/Sandoz, Horizon, Immunic AG, Neuron23, Novartis, Sanofi, Siemens, and TG Therapeutics, and received research support from Genentech. S.L.H. currently serves on the scientific advisory board of Accure, Alector, and Annexon; board of directors of Neurona; and has previously consulted for BD, Moderna, and NGM Bio. Dr. Hauser also has received travel reimbursement and writing support from F. Hoffmann-La Roche and Novartis AG for anti-CD20 therapy-related meetings and presentations and is supported by grants from the NIH/NINDS (R35NS111644). R.G. H. has received fees for consultation from Roche/Genentech, Novartis, Neuron23, QIA Consulting, and research funding from Roche/Genentech and Atara. H.L. has received research support from the US Department of Defense and Octave Bioscience, Inc. A.P. is currently an employee of Moderna Therapeutics. F.Q. is an employee of Octave Bioscience, Inc. N.S. has received the Sylvia Lawry Physician Fellowship Award from the National MS Society. She has also received compensation for consulting from EMD Serono. H.W. has received research support from the Department of Defense, Genentech, Inc., National Institutes of Health, National Multiple Sclerosis Society, Novartis, and Sanofi Genzyme. He has received compensation for consulting from Genentech, Inc., IM Therapeutics, IMAB Biopharma, MedDay Pharmaceuticals, Tiziana Life Sciences, and vTv Therapeutics. S.E.B. is co-Founder of Mate Bioservices. H.Y., R.G., S.S., S.J.C., and A.S. declare no competing interests.